StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Iovance Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$264.18M. For fiscal 2025 it was -$302.41M. The highest annual figure on record is -$14.45K in fiscal 2009.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$302.41M–
FY2024Dec 31, 2024-$352.98M–
FY2023Dec 31, 2023-$361.82M–
FY2022Dec 31, 2022-$292.76M–
FY2021Dec 31, 2021-$227.94M–
FY2020Dec 31, 2020-$205.13M–
FY2019Dec 31, 2019-$158.89M–
FY2018Dec 31, 2018-$101.25M–
FY2017Dec 31, 2017-$78.71M–
FY2016Dec 31, 2016-$32.67M–
FY2015Dec 31, 2015-$18.38M–
FY2014Dec 31, 2014-$8.63M–
FY2013Dec 31, 2013-$3.66M–
FY2012Dec 31, 2012-$2.24M–
FY2011Dec 31, 2011-$6.19M–
FY2010Dec 31, 2010-$620.81K–
FY2009Dec 31, 2009-$14.45K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$60.84M–
Q1 FY2026Mar 31, 2026-$72.07M–
Q4 FY2025Dec 31, 2025-$52.57M–
Q3 FY2025Sep 30, 2025-$78.70M–
Q2 FY2025Jun 30, 2025-$67.45M–
Q1 FY2025Mar 31, 2025-$103.69M–
Q4 FY2024Dec 31, 2024-$73.30M–
Q3 FY2024Sep 30, 2024-$58.97M–
Q2 FY2024Jun 30, 2024-$98.43M–
Q1 FY2024Mar 31, 2024-$122.28M–
Q4 FY2023Dec 31, 2023-$83.97M–
Q3 FY2023Sep 30, 2023-$84.08M–
Q2 FY2023Jun 30, 2023-$93.95M–
Q1 FY2023Mar 31, 2023-$99.82M–
Q4 FY2022Dec 31, 2022-$77.67M–
Q3 FY2022Sep 30, 2022-$63.65M–
Q2 FY2022Jun 30, 2022-$77.64M–
Q1 FY2022Mar 31, 2022-$73.80M–
Q4 FY2021Dec 31, 2021-$53.85M–
Q3 FY2021Sep 30, 2021-$57.69M–
Q2 FY2021Jun 30, 2021-$54.01M–
Q1 FY2021Mar 31, 2021-$62.39M–
Q4 FY2020Dec 31, 2020-$62.69M–
Q3 FY2020Sep 30, 2020-$40.52M–
Q2 FY2020Jun 30, 2020-$36.64M–
Q1 FY2020Mar 31, 2020-$65.29M–
Q4 FY2019Dec 31, 2019-$53.82M–
Q3 FY2019Sep 30, 2019-$42.18M–
Q2 FY2019Jun 30, 2019-$33.80M–
Q1 FY2019Mar 31, 2019-$29.09M–
Q4 FY2018Dec 31, 2018-$31.55M–
Q3 FY2018Sep 30, 2018-$27.93M–
Q2 FY2018Jun 30, 2018-$23.92M–
Q1 FY2018Mar 31, 2018-$17.85M–
Q4 FY2017Dec 31, 2017-$20.96M–
Q3 FY2017Sep 30, 2017-$21.45M–
Q2 FY2017Jun 30, 2017-$17.50M–
Q1 FY2017Mar 31, 2017-$18.80M–
Q4 FY2016Dec 31, 2016-$12.16M–
Q3 FY2016Sep 30, 2016-$12.21M–

More Iovance Biotherapeutics figures

See a number that looks wrong?